Panagiotis Zagaliotis

ORCID: 0000-0002-4669-957X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Synthesis and biological activity
  • Antibiotic Resistance in Bacteria
  • Bacteriophages and microbial interactions
  • Antifungal resistance and susceptibility
  • Fungal Infections and Studies
  • Nail Diseases and Treatments
  • Computational Drug Discovery Methods
  • SARS-CoV-2 and COVID-19 Research
  • Inflammatory mediators and NSAID effects
  • Research on Leishmaniasis Studies
  • Synthesis and Biological Evaluation
  • Synthesis of β-Lactam Compounds
  • Bacterial Genetics and Biotechnology
  • Enterobacteriaceae and Cronobacter Research
  • Synthesis and Characterization of Heterocyclic Compounds
  • Pharmacological Receptor Mechanisms and Effects
  • Gut microbiota and health
  • Cancer therapeutics and mechanisms
  • Hepatitis B Virus Studies

Cornell University
2020-2024

Weill Cornell Medicine
2021-2024

Aristotle University of Thessaloniki
2018-2024

Hippocration General Hospital
2022

<ns3:p>Invasive fungal diseases due to resistant yeasts and molds are an important increasing public health threat, likely a growing population of immunosuppressed hosts, increases in antifungal resistance, improvements laboratory diagnostics. The significant morbidity mortality associated with these pathogens bespeaks the urgent need for novel safe effective therapeutics. This review highlights promising investigational agents clinical phases development: fosmanogepix, ibrexafungerp,...

10.12688/f1000research.28327.1 preprint EN cc-by F1000Research 2021-06-28

Since the time of its appearance until present, COVID-19 has spread worldwide, with over 71 million confirmed cases and 1.6 deaths reported by World Health Organization (WHO). In addition to fact that are increasing Delta Omicron variants have also made situation more challenging. Herein, we report evaluation several thiazole/thiadiazole/benzothiazole based thiazolidinone derivatives which were chosen from 112 designed docking as potential molecules inhibit main protease SARS-CoV-2. The...

10.3390/molecules27072180 article EN cc-by Molecules 2022-03-28

Abstract Background Sargramostim (yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) augments innate and adaptive immune responses accelerates hematopoietic recovery of chemotherapy-induced neutropenia. However, considerably less is known about its efficacy as adjunctive immunotherapy against invasive fungal diseases (IFDs). Methods The clinical courses 15 patients with pediatric malignancies IFDs treated adjunctively sargramostim at...

10.1093/ofid/ofac535 article EN cc-by-nc-nd Open Forum Infectious Diseases 2022-10-11

<ns3:p>Invasive fungal diseases due to resistant yeasts and molds are an important increasing public health threat, likely a growing population of immunosuppressed hosts, increases in antifungal resistance, improvements laboratory diagnostics. The significant morbidity mortality associated with these pathogens bespeaks the urgent need for novel safe effective therapeutics. This review highlights promising investigational agents clinical phases development: fosmanogepix, ibrexafungerp,...

10.12688/f1000research.28327.2 preprint EN cc-by F1000Research 2022-01-12

Major obstacles faced by the use of nonsteroidal anti-inflammatory drugs (NSAID) are their gastrointestinal toxicity induced non-selective inhibition both cyclooxygenases (COX) 1 and 2 cardiotoxicity associated with a certain class COX-2 selective inhibitors. Recent studies have demonstrated that COX-1 generates compounds no gastric damage. The aim current study is to develop novel agents better profile. In our previous paper, we investigated activity 4-methylthiazole-based thiazolidinones....

10.3390/molecules28083416 article EN cc-by Molecules 2023-04-12

ABSTRACT Background Carbapenemase producing Klebsiella pneumoniae (KPC) are globally emerging pathogens which that cause life-threatening infections. Novel treatment alternatives urgently needed. Methods We therefore investigated the effectiveness of three novel bacteriophages (Spivey, Pharr and Soft) in a neutropenic murine model KPC gastrointestinal colonization, translocation, disseminated infection. Bacteriophage efficacy was determined by residual bacterial burden kidneys. Parallel...

10.1101/2024.06.21.600121 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-06-22

A series of previously synthesized 5-benzyliden-2-(5-methylthiazole-2-ylimino)thiazoli- din-4-one were evaluated for their anti-inflammatory activity on the basis PASS predictive outcomes. The compounds found to demonstrate moderate good activity, and some them displayed better than indomethacin used as reference drug. Structure–activity relationships revealed that depends not only nature substituent but also its position in benzene ring. most active selected investigate possible mechanism...

10.3390/molecules27238137 article EN cc-by Molecules 2022-11-22

ABSTRACT Carbapenemase-producing Klebsiella pneumoniae (KPC) are globally emerging pathogens that cause life-threatening infections. Novel treatment alternatives urgently needed. We therefore investigated the effectiveness of three novel bacteriophages (Spivey, Pharr, and Soft) in a neutropenic murine model KPC gastrointestinal colonization, translocation, disseminated infection. Bacteriophage efficacy was determined by residual bacterial burden (CFU/g) kidneys. Parallel studies were...

10.1128/aac.00919-24 article EN cc-by Antimicrobial Agents and Chemotherapy 2024-12-20

Carbapenem‐resistant Enterobacteriaceae (CRE) are a group of Gram‐negative bacterial pathogens which carry resistance to large proportion available antibiotics and significant cause nosocomial infection in the United States. Within this group, Klebsiella pneumoniae carrying bla KPC carbapenemase gene (KPC+) particular concern hospital setting among immunocompromised patients, strains sequence type (ST) 258 prevalent US, South America Europe. Bacteriophages, viruses, have been proposed as...

10.1096/fasebj.2020.34.s1.00500 article EN The FASEB Journal 2020-04-01
Coming Soon ...